Anti-inflammatory drugs have long served as a cornerstone in the treatment of conditions marked by inflammation, pain, and fever. At the heart of many of these therapeutic agents lies the inhibition ...

Farmingham, CT - A new mouse study published this week provides some insight into understanding why rofecoxib (Vioxx, Merck) and the other cyclooxygenase (COX)-2 inhibitors increase the risk of ...

The recent withdrawal of rofecoxib (Vioxx) from the market has intensified controversy about the safety of cyclooxygenase (COX)-2 inhibitors. Results from several recently published studies address ...

NEW YORK, Nov 13 (Reuters) - Tests of a new arthritis drug awaiting U.S. approval showed patients did not have a higher risk of a heart attack than those taking an older drug, but critics said the ...

Cyclooxygenase-2 (COX-2) inhibitors have long been employed to modulate inflammatory responses in a range of conditions, from arthritis to malignancies. In recent years, the convergence of ...